Floatz logo

NEPENTHE

Chronic Pain

Bursa City HospitalSmall moleculePhase 4 / ApprovedActive
BBB
74/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
75/ 100
Competitive Position
73/ 100

Competitive context

100 Active assets in the Chronic Pain cohort.

Asset / SponsorPhaseRating
(±)-TRAMADOL
EMS
Phase 4BBB
METHADONE
Cari Health Inc.
Phase 4BBB
LIDOCAINE
National and Kapodistrian University of Athens
Phase 4BBB
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE
Stanford University
Phase 4BBB
FENTANYL
Aga Khan University
Phase 4BBB

View all 50 →

Same molecule, other indications

NEPENTHE is also rated in:

PainDormant
BBB
Indicative ·
77 / 100
View asset →
cancer of unknown primary siteDormant
BBB
Indicative ·
75 / 100
View asset →
AnalgesiaDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →